Science Corp, led by Max Hodak, will test its biohybrid brain sensor in humans under Dr. Murat Günel’s guidance. The implant, which sits on the cortex inside the skull and uses 520 electrodes, will first be tried without neurons in patients already undergoing craniotomy. The long-term goal is to integrate lab-grown neurons with electronics to treat stroke, spinal injuries and Parkinson’s.

• Science Corp is placing its first biohybrid brain sensor (520 electrodes, pea-sized) in humans, led by Yale neurosurgeon Dr. Murat Günel, without seeking FDA approval by piggybacking on routine craniotomies.
• Initial trials will test only the electronic sensor without lab-grown neurons, with the neuron-integration technology planned for later stages.
• The company raised $230 million at a $1.5 billion valuation, and its more advanced product PRIMA is awaiting European approval to restore vision in macular degeneration patients.
• Günel argues coupling electronics with transplanted neurons could protect neural circuits and slow diseases like Parkinson's in ways pure electrical stimulation cannot, though he calls a 2027 human trial timeline ambitious.